Summary updated in July 2014 by Peter Renner and Markus Horneber
The potential value of any individual GLP-1 claim depends on the severity of the plaintiffs injuries, the strength of the evidence, and a range of other case-specific factors
9 Clinical trials have demonstrated that it can reduce HbA1c levels when added to metformin, and patients experience an average reduction of over 15% in body weight
When medication is appropriate, the discussion should include: The limited evidence for GLP-1 agonists specifically in BED FDA-approved alternatives, including lisdexamfetamine Realistic expectations about outcomes and timeline Potential side effects and monitoring requirements Cost considerations and insurance coverage The importance of combining medication with behavioral interventions Monitoring during treatment should be systematic and multifaceted
Creatine supports cutting goals in two direct ways: it helps maintain training intensity when your energy intake is lower, and it protects lean muscle through osmotic and cellular mechanisms
Sometimes yes, sometimes no depending on your plan, the medication, and your diagnosis